Clinical Trial

HB-adMSCs for the Treatment of Crohn's Disease

Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
Methodology: Randomized, double-blind, efficacy and safety study of allogeneic HB-adMSCs vs placebo for the treatment of Crohn's Disease with a 16-week treatment period and a safety and efficacy follow up period for 52 weeks post first treatment. Treatment Duration: 16 weeks General Objectives: To assess the efficacy and safety of multiple intravenous infusions of allogeneic HB-adMSCs by improving signs and symptoms of Crohn's Disease in this subject population. Number of Subjects: 46 (23 in each treatment arm) Indication: Crohn's Disease
Protocol Amendment History 6 amendments
This ClinicalTrials.gov record has been amended 6 times since 2025-07-11; most recent amendment 2026-06-15.
Status change: Not Yet Recruiting → Recruiting 2025-09-05
Trial Details
NCT Number NCT07077746
Lead Sponsor Hope Biosciences Research Foundation
Conditions Crohn Disease (CD)
Enrollment 46 participants
Start Date 2026-07-14
Primary Completion 2027-12 (estimated)
Study Completion 2027-12 (estimated)
Updated on ClinicalTrials.gov 2026-08-06